Non-invasive Prenatal Testing Market

Non-invasive Prenatal Testing Market - By Product Type , By Method Type , By Application Type , By End User & Global Region - Market Size, Trends, Share & Forecast 2020-2025

Request Sample Request Discount
  • Status : Upcoming
  • Published on: Jan 2021
  • Report ID: KDMI-6850
  • Available Format: PDF/Excel/DOC


Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Non-invasive Prenatal Testing Market

Request Sample

Technological advancements have not only served as a helping hand to the entire mankind but have also proven to be massively beneficial in curbing sufferings of people by enabling the implementation of preventive measures in various fields, especially in the medical field. With the emergence of innovative diagnostic and screening techniques, and innumerable advancements in the healthcare industry, several methods of genetic testing among other testing’s having gained popularity. The Non-invasive prenatal testing stands as one of the most distinctive technologies in addressing the concerns related to genetic diseases. The Non-invasive prenatal testing (NIPT), also known as cell-free DNA testing is nascent genetic processes of examining a fetal cell free DNA, present in the mothers blood serum for detecting common fetal aneuploidies. It is carried out through methods such as ultrasound detection, biochemical screening tests etc. which can indicate if pregnancy is at low risk or high risk for common chromosome disorders, including: Down syndrome (trisomy 21), (trisomy 18), (trisomy 13). Some of the NIPTs currently available worldwide are MaterniT21 PLUS, Harmony, Panorama, NIFTY, PrenaTest, BambniTest, and others. Global NIPT global market is expected to have a market worth of around $13.14 Billion by 2027, growing at a comprehensive CAGR of around 17.1% from 2019.


The growth of this market is attributed towards major relevant  factors including the increasing prevalence of chromosomal abnormalities with increasing maternal age, technological advancements in the healthcare industry such as wearable healthcare devices, sequencing technologies, regenerative medicine, genomic technologies, the expansion in the distribution services of the operating entities, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT.

Moreover, the evolution of prenatal testing, in the form of non-invasive tests serve as an intermediate step between screening and invasive tests in order to determine the probability of fetal abnormality as it offers detecting accuracy of more than 99% and displays screening in less time than other types of prenatal screening. Due to the rising incidence of miscarriage and complications and the increasing popularity among pregnant women as a lower-risk alternative to amniocentesis and awareness about prenatal genetic issues driving the non-invasive prenatal testing, it is predicted that non-invasive prenatal testing will become a standard test in the future, replacing other, and riskier screening tests. The development of NIPT for genetic conditions is a major commercial interest because of high demand in the disease segments such as Down syndrome.

Furthermore, as very few players offer non-invasive prenatal testing, several leading players are focusing on the development of more accurate and reliable NIPT for the analysis of cell-free fetal DNA (cffDNA) in a sample of maternal blood collected in the first trimester. Countries such as China, India, Brazil, and Mexico are already offering significant growth opportunities to market players. The high growth in these markets can majorly be seen due to the improving healthcare infrastructure, increasing public healthcare expenditure, the presence of a large target patient population, and growing awareness and availability of advanced technologies.

 However, lack of skilled professionals, reliability of test results, especially in obese women, high cost of testing and provisional tools for diagnosis are a few factors restraining the growth of this market.


By Product Type:

  • Consumables
  • Instruments
  • Services

By Method Type:

  • Biochemical Screening Tests
  • Ultrasound Detection
  • Cell-Free DNA in Maternal Plasma Tests
  • Fetal Cells in Maternal Blood Tests

By Application Type:

  • Trisomy
  • Microdeletion Syndrome
  • Others

By End User: 

  • Diagnostic Laboratories
  • Hospitals

By Region: 

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa


In 2019, North America accounted for the largest market share, followed by Europe because of factors including high diagnostic and treatment rate of trisomy disorders, high awareness for prenatal testing, presence of laboratories offering NIPT services, focus on improving technology and alliances and partnerships among key market players, high R&D investments, availability of technologically advanced healthcare research framework, the development of WGS in the region and also capital intensive. This trend is projected to grow throughout the next decade.

On the other hand,  due to high adoption rate of non-invasive prenatal tests, developing healthcare infrastructure, technological integration of NGS methodologies, rising awareness programs & conferences, clinical development frameworks in countries like India, Japan China, Australia and New Zealand, the Asia-Pacific region is expected to grow at the highest CAGR in the next few years.


  • Agilent Technologies Inc.
  • Berry Genetics Inc.
  • BGI Genomics Co. Ltd.
  • Eurofins LifeCodexx GmbH
  • F. Hoffmann-La Roche AG
  • GE Healthcare
  • Igenomix
  • Illumina Inc.
  • Laboratory Corporation
  • Natera Inc.
  • Perkinelmer Inc.
  • Thermo Fisher Scientific Inc.
  • Yourgene Health
  • Other Players


  • In January 2019, Illumina expanded its NIPT platform portfolio with the launch of its VeriSeq NIPT Solution v2.
  • In September 2020, Illumina (the gene sequencing giant that formed the cancer diagnostics developer and spun it out as a separate company four years ago) announced to Acquire Cancer Diagnostics Developer Grail in an $8B Deal.
  • In Oct 2020, Healthcare Insurer, Cantene extended coverage of Natera’s (a pioneer and global leader in cell-free DNA testing and non-invasive prenatal testing) panorama noninvasive prenatal test (NIPT) to all pregnant women in the regions where it provided its services.

Timeline Considered for Analysis:

- 2019: Base Year

- 2020: Estimated Year

- 2020 to 2025: Forecast Period

Research Scope and Deliverables

Overview & Executive Summary

Market Drivers, Trends, Challenges and Opportunities

Market Size and Forecast Projections

Macroeconomic Indicators of Various Countries Impacting the Growth of the Market

Extensive Coverage of Industry Players including Recent Product Launches and Market Activities

Porter’s Five Force Analysis

Market Segmentation Analysis:

Industry report analyses the global NIPT market by the following segments:

- Product Type

- Method Type

- Application Type

- End User

Customization: We also offer customization’s in the industry report as per the company’s specific needs.

Key Questions Answered in the Global NIPT Industry Report

  • What is the overall market size in 2019? What will be the market growth during the forecast period i.e. 2020-2025?
  • Which region would have high demand for product in the upcoming years?
  • What are the factors driving the growth of the market?
  • Which sub-market will make the most significant contribution to the market?
  • What are the market opportunities for existing and entry-level players?
  • What are various long-term and short-term strategies adopted by the market players?

Custom Research Requirement? Questions to ask?

Get in touch

Custom Research requirement.

Go Up